On July 6, 2023, the Board of Directors of Nabriva Therapeutics plc appointed H. Michael Hogan as Chief Executive Officer of the Company, effective as of the Naftzger Separation Date. Mr. Hogan will provide services as an executive officer of the Company pursuant to a consulting agreement to which the Company is a party with Armanino. Mr. Hogan, age 60, has served as a Partner at Armanino, since January 2021, and leads the firm’s Corporate Finance and Restructuring practices.

From October 2016 to January 2021, Mr. Hogan served as a Managing Director in Armanino’s Corporate Finance and Restructuring practice. Prior to his time at Armanino, Mr. Hogan served as a Managing Director at Sherwood Advisory Services, with a focus on advisory and managerial services for distressed companies. Mr. Hogan received a B.A. in Political Science and Economics from Colgate University.